Oxford Nanopore Divests Illumina's Stake, Ending Equity Relationship | GenomeWeb

This article has been updated to include Illumina's recorded gain on the sale.

NEW YORK (GenomeWeb News) – Oxford Nanopore Technologies today said that it has coordinated the acquisition of Illumina's 13.5 percent stake in the company on behalf of certain shareholders.

The unnamed investors acquired Illumina's shares for £56.4 million ($90.7 million), and Illumina said in a regulatory filing Friday that it has recorded a $55.2 million gain from the sale of its stake in Oxford Nanopore.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.